Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | GAPDH | P04406 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399463 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL12646732 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL21999056 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL12015181 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL12590125 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL18521948 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL18521951 | 1.00 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL24292047 | 0.92 | ADORA3 (0.61) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL25812959 | 0.92 | ADORA3 (0.61) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B | |
| SCHEMBL21999233 | 0.91 | ADORA3 (0.64) | ADORA3ADORA1SMN1; SMN2ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | claimed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220395465-A1 | STING AGONIST COMPRISING EXOSOMES COMBINED WITH IL-12 DISPLAYING EXOSOMES FOR TREATING A TUMOUR | CODIAK BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-5773603-A | ADENOSINE DEAMINASE INHIBITOR | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| US-5705491-A | Adenosine deaminase inhibitor | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0601322-A2 | Adenosindeaminase inhibitor | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0269574-B1 | NOVEL ADENOSINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS AN ACTIVE INGREDIENT | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4843066-A | HYPOTENSIVE AGENTS | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA3 110/4885ADORA1 32/4885SMN1; SMN2 3075/4885 |
| US-20220395465-A1 | STING AGONIST COMPRISING EXOSOMES COMBINED WITH IL-12 DISPLAYING EXOSOMES FOR TREATING A TUMOUR | STING1, MAVS, BID | ADORA3 1249/4885ADORA1 601/4885SMN1; SMN2 2452/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA3 117/4885ADORA1 33/4885SMN1; SMN2 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.